Audited Financial Results of the Company for the quarter and year ended March 31, 2026 along with Statutory Auditor''s Report thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Link Pharma Chem Ltd reported a turnaround from loss to profit for FY2026. Total income increased to Rs 2,763.49 Lakhs from Rs 2,561.99 Lakhs in the previous year, representing approximately 7.86% revenue growth. The company swung from a loss of Rs 102.73 Lakhs in FY2025 to a profit of Rs 7.69 Lakhs in FY2026. However, the Q4 March 2026 quarter showed a loss of Rs 40.86 Lakhs despite revenue of Rs 658.88 Lakhs. The auditors issued an unmodified opinion with no qualifications. Cash flow from operations remained positive at Rs 214.65 Lakhs, and the company also reported other comprehensive income of Rs 4.96 Lakhs.
The company returned to profitability after two consecutive loss-making years, which is a positive sign. However, the profit margin remains extremely thin (0.28% PAT margin) and the Q4 loss raises concerns about the sustainability of this recovery. Shareholders should monitor whether this is a genuine turnaround or a one-time improvement.